| CIMAX | RAZAX | CIMAX / RAZAX | |
| Total Expense Ratio | 0.59 | 1.14 | 52% |
| Annual Report Gross Expense Ratio | 0.59 | 1.32 | 45% |
| Fund Existence | 24 years | 8 years | - |
| Gain YTD | 13.950 | 14.047 | 99% |
| Front Load | 4% | 6% | 61% |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 138B | 577M | 23,917% |
| Annual Yield % from dividends | 3.57 | 3.16 | 113% |
| Returns for 1 year | 9.74 | 12.54 | 78% |
| Returns for 3 years | 29.12 | 41.58 | 70% |
| Returns for 5 years | 39.98 | 25.83 | 155% |
| Returns for 10 years | 78.49 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPIE | 46.27 | 0.01 | +0.02% |
| JPMorgan Income ETF | |||
| CPNS | 26.98 | N/A | +0.01% |
| Calamos Nasdaq-100 Str Alt Prt ETF-Sep | |||
| PFO | 9.51 | N/A | N/A |
| Flaherty & Crumrine Preferred and Income Opportunity Fund | |||
| JUNT | 35.48 | -0.08 | -0.22% |
| AllianzIM U.S. Large Cp Buffer10 Jun ETF | |||
| HQL | 17.18 | -0.07 | -0.41% |
| abrdn Life Sciences Investors | |||